Cerevel Therapeutics Holdings, Inc. (CERE) Comparison with companies in other sectors?

Cerevel Therapeutics Holdings, Inc. has a share price of 182.20M. You can analyze Cerevel Therapeutics Holdings, Inc. (CERE) competitors across different market sectors through stock heatmaps.

What are CERE's NET and operating margins?

Cerevel Therapeutics Holdings, Inc. (CERE) operating margin is around -34.23, and net profit margin is approximately -32.08 as of the latest reports.

In what way does CERE's earnings per share (EPS) trend reflect its financial momentum?

Cerevel Therapeutics Holdings, Inc. (CERE) EPS is -2.73 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Cerevel Therapeutics Holdings, Inc. is -16.47, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Cerevel Therapeutics Holdings, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Cerevel Therapeutics Holdings, Inc. like P/E which is -30.86, P/B which is 14.47, and PEG which is 13.73. Compare them with sector averages to evaluate if the stock is priced fairly.

Cerevel Therapeutics Holdings, Inc.

CERE•NASDAQ

Healthcare

Biotechnology

$44.96

$0.33(0.74%)

Fundamental Analysis of Cerevel Therapeutics Holdings, Inc. (CERE)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-2.73

P/E Ratio

-16.47

ROE

-0.43%

Net Margin

-32.08%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$8.19B

Shares OutstandingTotal number of shares issued

$182.20M

Book Value/ShareNet worth per share

$3.11

Revenue/ShareAnnual revenue per share

$0.05

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-2.73

Net MarginNet income as percentage of revenue

-3208.49%

Operating MarginOperating income as percentage of revenue

-3422.51%

ROEReturn on shareholders' equity

-42.73%

ROAReturn on total assets

-23.47%

ROCEReturn on capital employed

-27.05%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-1.20

Cash/ShareCash and equivalents per share

$4.66

FCF YieldFree cash flow as percentage of market cap

-2.66%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for CEREFinancial Ratios Analysis details for CERE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for CERESector Benchmarking details for CERE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Cerevel Therapeutics Holdings, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Cerevel Therapeutics Holdings, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Cerevel Therapeutics Holdings, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Cerevel Therapeutics Holdings, Inc.

For Cerevel Therapeutics Holdings, Inc., essential financial indicators include EPS -2.73, PE -16.47, and ROE -0.43. These key ratios reveal insights into Cerevel Therapeutics Holdings, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Cerevel Therapeutics Holdings, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Cerevel Therapeutics Holdings, Inc.

Metrics like Net Margin -3208.49% and ROA -23.47% shed light on how well Cerevel Therapeutics Holdings, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Cerevel Therapeutics Holdings, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Cerevel Therapeutics Holdings, Inc.

Using ratios such as P/B Ratio 14.47 and PEG Ratio 13.73, investors can assess whether Cerevel Therapeutics Holdings, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Cerevel Therapeutics Holdings, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Cerevel Therapeutics Holdings, Inc.

Financial health indicators, such as Debt/Equity Ratio 0.65 and Cash Flow $-1.20, provide a snapshot of Cerevel Therapeutics Holdings, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Cerevel Therapeutics Holdings, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Cerevel Therapeutics Holdings, Inc.

Investing in Cerevel Therapeutics Holdings, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Cerevel Therapeutics Holdings, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;